Literature DB >> 10980261

Involvement of direct inhibition of NMDA receptors in the effects of sigma-receptor ligands on glutamate neurotoxicity in vitro.

H Nishikawa1, A Hashino, T Kume, H Katsuki, S Kaneko, A Akaike.   

Abstract

This study was performed to examine the roles of the N-methyl-D-aspartate (NMDA) receptor/phencyclidine (PCP) channel complex in the protective effects of sigma-receptor ligands against glutamate neurotoxicity in cultured cortical neurons derived from fetal rats. A 1-h exposure of cultures to glutamate caused a marked loss of viability, as determined by Trypan blue exclusion. This acute neurotoxicity of glutamate was prevented by NMDA receptor antagonists. Expression of sigma(1) receptor mRNA in cortical cultures was confirmed by reverse transcription polymerase chain reaction (RT-PCR). sigma Receptor ligands with affinity for NMDA receptor channels including the PCP site, such as (+)-N-allylnormetazocine ((+)-SKF10,047), haloperidol, and R(-)-N-(3-phenyl-1-propyl)-1-phenyl-2-aminopropane ((-)-PPAP), prevented glutamate neurotoxicity in a concentration-dependent manner. In contrast, other sigma-receptor ligands without affinity for NMDA receptors, such as carbetapentane and R(+)-3-(3-hydroxyphenyl)-N-propylpiperidine ((+)-3-PPP), did not show neuroprotective effects. Putative endogenous sigma receptor ligands such as pregnenolone, progesterone, and dehydroepiandrosterone did not affect glutamate neurotoxicity. The protective effects of (+)-SKF10,047, haloperidol, and (-)-PPAP were not affected by the sigma(1) receptor antagonist rimcazole. These results suggested that a direct interaction with NMDA receptors but not with sigma receptors plays a crucial role in the neuroprotective effects of sigma receptor ligands with affinity for NMDA receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980261     DOI: 10.1016/s0014-2999(00)00595-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Systematic review of the pharmacological agents that have been tested against spreading depolarizations.

Authors:  Anna Klass; Renan Sánchez-Porras; Edgar Santos
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-20       Impact factor: 6.200

3.  Analysis of sigma receptor (sigmaR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice.

Authors:  M Shamsul Ola; Pamela Moore; Dennis Maddox; Amira El-Sherbeny; Wei Huang; Penny Roon; Neeraj Agarwal; Vadivel Ganapathy; Sylvia B Smith
Journal:  Brain Res Mol Brain Res       Date:  2002-11-15

4.  The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice.

Authors:  Maninder Malik; Claudia Rangel-Barajas; Nathalie Sumien; Chang Su; Meharvan Singh; Zhenglan Chen; Ren-Qi Huang; Johann Meunier; Tangui Maurice; Robert H Mach; Robert R Luedtke
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

5.  A prototypical Sigma-1 receptor antagonist protects against brain ischemia.

Authors:  John A Schetz; Evelyn Perez; Ran Liu; Shiuhwei Chen; Ivan Lee; James W Simpkins
Journal:  Brain Res       Date:  2007-09-12       Impact factor: 3.252

6.  Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET.

Authors:  Amira K Brown; Yasuyuki Kimura; Sami S Zoghbi; Fabrice G Siméon; Jeih-San Liow; William C Kreisl; Andrew Taku; Masahiro Fujita; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2008-12       Impact factor: 10.057

7.  Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.

Authors:  Stéphane Bastianetto; Marc Danik; Françoise Mennicken; Sylvain Williams; Rémi Quirion
Journal:  BMC Neurosci       Date:  2006-03-30       Impact factor: 3.288

Review 8.  Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders.

Authors:  Kinga Sałaciak; Karolina Pytka
Journal:  Neurosci Biobehav Rev       Date:  2021-11-01       Impact factor: 8.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.